Aquestive Therapeutics (NASDAQ:AQST) Director Richard Daly Purchases 28,025 Shares of Company Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Richard Daly purchased 28,025 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was acquired at an average cost of $3.54 per share, with a total value of $99,208.50. Following the completion of the acquisition, the director directly owned 28,025 shares in the company, valued at $99,208.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $3.57 on Friday. The company has a 50-day moving average of $4.40 and a 200-day moving average of $4.21. Aquestive Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $6.74.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, November 3rd. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $7.56 million for the quarter, compared to analyst estimates of $11.02 million. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on AQST. Wall Street Zen lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Thursday, October 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, October 16th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. StoneX Group Inc. purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth approximately $70,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Aquestive Therapeutics during the third quarter worth approximately $30,000. Profund Advisors LLC grew its position in Aquestive Therapeutics by 497.9% during the third quarter. Profund Advisors LLC now owns 195,758 shares of the company’s stock valued at $906,000 after purchasing an additional 163,019 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Aquestive Therapeutics by 14.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company’s stock valued at $107,000 after buying an additional 2,936 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $210,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.